Case-only approach to identifying markers predicting treatment effects on the relative risk scale.

ABSTRACT: Retrospectively measuring markers on stored baseline samples from participants in a randomized controlled trial (RCT) may provide high quality evidence as to the value of the markers for treatment selection. Originally developed for approximating gene-environment interactions in the odds ratio scale, the case-only method has recently been advocated for assessing gene-treatment interactions on rare disease endpoints in randomized clinical trials. In this article, the case-only approach is shown to provide a consistent and efficient estimator of marker by treatment interactions and marker-specific treatment effects on the relative risk scale. The prohibitive rare-disease assumption is no longer needed, broadening the utility of the case-only approach. The case-only method is resource-efficie

SUBMITTER: Dai JY 

PROVIDER: S-EPMC5874156 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature